Citurgia Biochemicals Limited has secured approval from the Registrar of Companies (ROC), Mumbai, to extend the deadline for its 51st Annual General Meeting (AGM). The regulatory body granted a one-month extension, allowing the company to convene the meeting by October 31, 2026, for the financial year ended March 31, 2026.

The company initially sought a three-month extension until December 31, 2025, following a board resolution dated August 31, 2026. However, the ROC approved only the one-month extension in its letter dated September 18, 2026.

Regulatory Context

The approval was issued under Section 96(1) of the Companies Act, 2013. The original statutory deadline for holding the AGM was September 30, 2026. The company filed its application with the SRN AC5761930 on September 1, 2026.

Compliance Advisory

In its order, the ROC advised Citurgia Biochemicals to ensure careful compliance with the provisions of the Companies Act, 2013, in future filings. The company stated it will intimitate the specific date of the AGM within the extended timeline in due course.

This disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Citurgia Biochemicals Limited reported a standalone loss of ₹8.20 lakh for the quarter ended June 30, 2026 (Q1FY27). The loss narrowed significantly from ₹8.39 lakh in the corresponding quarter of FY26, driven by a reduction in operational expenses despite zero revenue generation.

The Mumbai-based biochemical firm disclosed zero total income from operations for Q1FY27, consistent with its performance in the preceding quarter and the full year ended March 31, 2026. The Board of Directors approved the unaudited financial results on August 14, 2026.

Financial Performance

The company’s expense structure contracted sharply in the current quarter compared to the previous period. Total expenses fell to ₹8.20 lakh from ₹25.82 lakh in Q4FY26. This decline was primarily attributable to lower other expenses, which dropped to ₹0.05 lakh from ₹14.15 lakh in the preceding quarter.

Employee benefit expenses remained stable at ₹3.00 lakh, while depreciation and amortisation costs decreased slightly to ₹5.15 lakh from ₹5.73 lakh. For the full fiscal year 2026, the company incurred a total loss of ₹74.25 lakh against nil revenue.

What the Numbers Show

The absence of any operating income or other income indicates that the company is not currently generating cash flows from business activities. The profit before tax matches the total expenses exactly, confirming that the entire loss is driven by fixed overheads such as employee benefits and depreciation rather than variable costs linked to production or sales volume.